Nivalis to price its IPO of 4,285,714 shares between $13.00 and $15.00

Financing to be conducted by Cowen, Stifel, Baird and H.C. Wainwright

By Devika Patel

Knoxville, Tenn., June 3 – Nivalis Therapeutics, Inc. will sell 4,285,714 common shares in its initial public offering with a 30-day greenshoe of 642,857 additional shares, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission. The company has registered up to $73,928,565 of stock for the deal, which was announced on May 13.

The shares will be sold at a price expected to fall between $13.00 and $15.00 per share.

Cowen and Co. LLC and Stifel, Nicolaus & Co., Inc. are the bookrunners. Robert W. Baird & Co. Inc. and H.C. Wainwright & Co., LLC are the co-managers.

Proceeds will be used for clinical programs and development activities and for working capital and other general corporate purposes, including operations.

The clinical-stage pharmaceutical company is based in Boulder, Colo. The company intends to list its common stock on the Nasdaq under the symbol “NVLS.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.